The future home of the UTC School of Nursing, the Dorothy and Jim Kennedy Health Sciences Building, broke ground on Monday. Located at the corner of Palmetto and East 3rd streets, this new ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...

Exact Sciences Corp ( (EXAS)) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors. Exact Sciences Corp. is a prominent company in ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands ...

Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion. William Blair notes that management attributed the lower-than-expected guidance ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...